Preladenant

Drug Profile

Preladenant

Alternative Names: MK-3814; Privadenant; SCH 420814

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough
  • Class Antiparkinsonians; Bridged-ring heterocyclic compounds; Piperazines; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Parkinson's disease

Most Recent Events

  • 24 Nov 2017 Merck terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA, Canada, Israel, because the data did not support study endpoints (PO) (NCT03099161)
  • 27 Jun 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel (PO) (NCT03099161)
  • 21 Apr 2017 Merck terminates a phase II trial in Drug-induced akathisia in South Africa (PO) (NCT00693472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top